Table Of Content

Journal of Pharmacokinetics and Biopharmaceutics, Vol. 20, No. 6, 1992 Author Index to Volume 20 Ambros, Reinhard J., 421 Mandema, Jaap W., 511 Modi, Nishit B., 397 Barfknecht, Charles F., 357 Berner, Bret, 443 Ong, Huy, 461 Burke, Martin, 559 Burnette, Ronald R., 477 Pang, K. Sandy, 105, 253 Perreault, Sylvie, 461 Davidian, Marie, 531 Phillips, Kern F., 380 Dedrick, Robert L., 95 Pond, Susan M., 19 Dewitte, Wayne, 443 Purves, Robert D., 211, 501 Diaz-Garcia, Juan M., 171 Diletti, Edgar, 559 Donoho, David, L., 63 Rao, Chakradhara S., 357 du Souich, Patrick, 461 Rivory, Laurent P., 19 Roberts. Michael S., 19 Endrenyi, Laszlo, 279 Rodriguez, Carlos A., 195 Evans, Allan M., 171 Rowland, Malcolm, 171 Fisher, Lynn E., 319 Sambol, Nancy, 443 Fung, Ho-Leung, 227 Schoenwald, Ronald D., 357 Shafer, Steven L., 63, 147 Gallant, A. Ronald, 531 Sheiner, Lewis B., 511 Grasela, Thaddeus H., 295, 393 Siegel, Ronald A., 413 Gregg, Keith M., 147 Smith, David E., 195 Guillard, Stephanie, 195 St-Pierre, Marie V., 105 Steinijans, Volker W., 559 Hallak, Hussein O., I Stoeckel, Klaus, 421 Haughey, David B., 333 Hauschke, Dieter, 559 Tung, Ying, 393 Holford, Nicholas H. G., 421 Tzeng, Tsang-Bin, 227 Jusko, William J., 319, 333 Varvel, John R., 63 King, Franklin G., 95 Veng-Pedersen, 397 Kochak, Gregory M., 443 Verotta, Davide, 511 Laban, Saad L., 357 Walawander, Cynthia A., 295, 393 Leal, Marion, 443 Wedlund, Peter J., 1 Lee, Ping I., 105 Weiss, Michael, 253 Liu, Dong Y., 295 Weng, Jenny, 279 Ludwig, Elizabeth A., 319 White, Donald B., 295, 393 673 0090-466X/92/1200-0673$06.50/0 © 1992 Plenum Publishing Corporation i Journal of Pharmacokinetics and Biopharmaceutics, Vol 20, No. 6, 1992 Subject Index to Volume 20 Absorption models, 421 Generalized additive models, 511 Alkylphenylpropionic (or acetic), 358 Anesthesia, 63 Helper T lymphocytes, 333 Area-under-the-curve, 211, 501 Hepatic availability, 19 Axial tissue diffusion, 19 Hepatic blood flow, 19 Bioavailability, 421 Hepatic clearance, 107 Bioequivalence, 559 Hepatic elimination, 19, 171 Hypothesis testing, 295 Cefetamet, 421 Cell trafficking, 333 Immunosuppression, 333 Chlorothiazide, 195 Infusion pump, 63 Chronopharmacokinetics, 477 Infusions, 147 Chronopharmacology, 333 Isolated perfused rat liver, 171 Circadian rhythm, 477 Isomeric organic mononitrates, 211 Circulation time distribution, 253 O'5-dichlorodiammine-platinum, 95 Large-sampled method, 279 Cisplatin, 95 Likelihood ratio test, 295 Clinical trials, 295 Linear systems analysis, 477 Computational efficiency, 279 Lipophilic drugs, 19 Computer driven, 147 Computer simulation, 279 Maximum likelihood, 531 Computer-assisted equipment, 63 Metabolite formation and elimination, 107 Computers, 147 Metabolite kinetics, 19 Confidence intervals, 295 Methylprednisolone, 333 Curve moments, 253 Mixing curve, 253 MKMODEL, 421 Density estimation, 531 Model building, 511 Diazepam, 171 Moment analysis, 501 Dispersion model, 19, 107, 171 Monoexponential model, 295 Distributed-tube model, 19 Multiplicative model, 559 Drug delivery, 147 Nitroglycerin, 443 Drug disposition curve, 253 Non-compartmental analysis, 253, 211, 501 Dynamics, 461 Noneliminating and eliminating system, 253 Dynamics of drug distribution, 253 Nonlinear mixed effects models, 531 NONMEM, 279, 295, 421, 511 Effect site, 147 Nonparametric estimation, 531 Enzyme heterogeneity, 19 Nonsteroidal antiinflammatory agents, 358 Experimental design, 279 Numerical integration, 211 First pass effect, 461 Ocular pharmacokinetics, 358 Fixed effect variance, 443 Flow dependence, 1 Parallel-tube model, 19, 107 Flow heterogeneity, 19 Parameter estimation, 279 0(»0-466X/92/l200-0675$06.50/0 © 1992 Plenum Publishing Corporation 676 Subject Index Perfusion flow rate, 195 Residence time distribution, 253 Pharmacodynamic modeling, 211 Reversible metabolism, 1 Pharmacodynamics, 147, 333 Route of administration, 461 Pharmacokinetic modeling, 1 Pharmacokinetic models, 477 Salbutamol, 461 Pharmacokinetics, 95, 147, 511 Sample size, 559 Physiological model, 95, 171 Sequential elimination, 107 Population analysis, 511 Simulations, 295 Population pharmacokinetics, 279, 295, 421, Skewing, 253 531 Surface activity, 358 Power, 295, 559 Predictive performance, 63 Tail correction, 501 Primary, secondary and tertiary metabolites, Transdermal delivery, 443 107 Protein binding, 19, 171 Variance, 253 Quinidine, 531 Variational stability, 443 Vasodilating potencies, 211 Rabbits, 358 Vitamin K, 1 Random intersubject and intrasubject vari¬ Vitamin K epoxide, 1 ance, 443 Rat IPK, 195 Warfarin, 1 Recirculation model, 253 Well-stirred model, 19, 107